Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Multicenter Phase II Clinical Study of QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer

NCT07286240 is registered in ClinicalTrials.gov with Affiliated Cancer Hospital & Institute of Guangzhou Medical University as lead sponsor.

NCT NCT07286240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07286240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Multicenter Phase II Clinical Study of QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer
Lead sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase
Phase 2
Overall status
Recruiting
Start date
November 15, 2025
Completion date
March 30, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

treatment of recurrent ovarian cancer